In an osteoporosis patient on denosumab (Prolia) with normal serum calcium, normal renal function, normal vitamin D, persistently elevated intact parathyroid hormone, markedly elevated 24‑hour urinary calcium, and negative neck sestamibi scan and 4‑dimensional CT, what is the next step in management?

Denosumab-Induced Normocalcemic Hyperparathyroidism: Continue Prolia with Enhanced Calcium/Vitamin D Supplementation

This is denosumab-induced normocalcemic hyperparathyroidism, a recognized compensatory response to the potent antiresorptive effect of Prolia, and you should continue denosumab while optimizing calcium and vitamin D supplementation rather than pursuing further parathyroid imaging or surgery.

Understanding the Clinical Picture

Your patient presents with a classic case of denosumab-induced secondary hyperparathyroidism. The elevated PTH (83-104 pg/mL) with normal serum calcium represents a compensatory physiological response to denosumab's powerful suppression of bone resorption 1, 2. The markedly elevated 24-hour urinary calcium (315 mg/day) actually indicates adequate calcium absorption and argues against primary hyperparathyroidism, which typically shows low-normal urinary calcium.

The negative imaging (sestamibi scan and 4D-CT) effectively rules out a parathyroid adenoma, which would be the concern in true primary hyperparathyroidism.

Why This Happens with Denosumab

Denosumab causes rapid and profound suppression of osteoclastic bone resorption within the first week of administration 3. This sudden decrease in calcium release from bone triggers a compensatory PTH elevation to maintain serum calcium homeostasis 2. Research demonstrates that:

• PTH levels increase significantly at 1 month post-denosumab, with mean increases of 30-64% above baseline 2
• This PTH elevation is more pronounced in older patients 4
• Elevated baseline PTH actually predicts hypocalcemia risk (AUC 0.668 for PTH >6.8 pmol/L) 5
• PTH levels typically normalize by 6 months with adequate supplementation 2, 6

Immediate Management Strategy

1. Increase Calcium and Vitamin D Supplementation

Based on the evidence, implement a loading regimen:

• Double-dose calcium/vitamin D for the first month after each denosumab injection: 2000 mg calcium carbonate + 1600 IU cholecalciferol daily for month 1, then reduce to standard 1000 mg/800 IU for months 2-6 2
• This regimen significantly reduces PTH elevation (mean change -3.0% vs +63.5% with standard dosing, p=0.029) 2
• Divide calcium doses to no more than 500-600 mg per administration for optimal absorption 7

2. Continue Denosumab on Schedule

Do not delay or discontinue denosumab 3. The evidence is clear that:

• Denosumab discontinuation causes rapid bone turnover rebound within 3-6 months 3
• BMD declines to pretreatment levels within 24 months of stopping 3
• Multiple severe vertebral fractures can occur after cessation 3
• Doses must be administered every 6 months without delay 3

3. Monitor Appropriately

Check the following 1 month after each denosumab injection:

• Serum calcium (albumin-adjusted)
• PTH
• 25-OH vitamin D (maintain >30 ng/mL)
• Consider serum phosphate in this patient given the elevated PTH 6

The 24-hour urinary calcium does not need repeated measurement unless you suspect hypercalciuria-related complications.

Key Clinical Pitfalls to Avoid

Do NOT pursue parathyroidectomy. With normal serum calcium, negative imaging, and the temporal relationship to denosumab initiation, this is not surgical disease 1. One case report documented PTH of 1350 pg/mL with denosumab that normalized to 71 pg/mL after temporary discontinuation and adequate supplementation 1—but remember, discontinuation carries fracture risk.

Do NOT stop denosumab due to elevated PTH alone. The antifracture benefits far outweigh this manageable biochemical finding 3. Studies in patients with actual primary hyperparathyroidism and CKD show denosumab is both safe and effective, with appropriate calcium monitoring 8.

Do NOT under-supplement calcium. The high urinary calcium (315 mg/day) indicates your patient is absorbing calcium well, but denosumab's potent bone effects require aggressive supplementation to prevent the PTH from driving excessive bone turnover or causing symptomatic hypocalcemia 5, 6.

Expected Trajectory

With enhanced supplementation, expect:

• PTH to peak at 1-3 months post-injection 6
• Gradual PTH decline toward baseline by 6 months 2, 6
• Maintained normal serum calcium 2
• Continued excellent BMD response to denosumab 3

If PTH remains persistently elevated >150 pg/mL despite optimized supplementation and normal vitamin D levels at 6 months, then consider endocrinology referral for further evaluation—but this scenario is uncommon with appropriate management 1, 2.